Who are CRMD-001-Deferiprone's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Avandia, Actigall, Lasix, Furadantin, artesunate and mefloquine, SFP.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/crmd-001-deferiprone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

CRMD-001-Deferiprone — Competitive Intelligence Brief

CRMD-001-Deferiprone (CRMD-001-Deferiprone) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Iron chelator. Area: Rare Disease.

phase 2 Iron chelator Iron Rare Disease Small molecule Live · refreshed every 30 min

Target snapshot

CRMD-001-Deferiprone (CRMD-001-Deferiprone) — CorMedix. Iron chelator

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
CRMD-001-Deferiprone TARGET	CRMD-001-Deferiprone	CorMedix	phase 2	Iron chelator	Iron
Avandia	ROSIGLITAZONE	Woodward	marketed	Peroxisome Proliferator Receptor gamma Agonist	CDGSH iron-sulfur domain-containing protein 1	1999-01-01
Actigall	URSODIOL	AbbVie	marketed	Bile Acid [EPC]	CDGSH iron-sulfur domain-containing protein 1	1987-01-01
Lasix	furosemide	Generic (originally Hoechst AG)	marketed	Loop Diuretic [EPC]	ATP-binding cassette sub-family G member 2, CDGSH iron-sulfur domain-containing protein 1, G-protein coupled receptor 35	1966-07-01
Furadantin	NITROFURANTOIN		marketed	Nitrofuran Antibacterial [EPC]	CDGSH iron-sulfur domain-containing protein 1	1953-01-01
artesunate and mefloquine	artesunate and mefloquine	Mepha Ltd.	marketed	Antimalarial combination	Plasmodium falciparum heme iron (artesunate); parasite digestive vacuole and mitochondria (mefloquine)
SFP	SFP	Rockwell Medical Technologies, Inc.	marketed	Intravenous iron replacement agent	Iron (Fe3+) for hemoglobin synthesis and erythropoiesis

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2034-04-03 — Lasix · 11433044 · Method of Use · US
2034-04-03 — Lasix · 9884039 · Method of Use · US
2034-04-03 — Lasix · 12370168 · Formulation · US
2034-04-03 — Lasix · 10272064 · Formulation · US

Sponsor landscape (Iron chelator class)

ApoPharma · 3 drugs in this class
Consorzio per Valutazioni Biologiche e Farmacologiche · 2 drugs in this class
American University of Beirut Medical Center · 1 drug in this class
Azienda Ospedaliera V. Cervello · 1 drug in this class
CorMedix · 1 drug in this class
The George Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CRMD-001-Deferiprone — Competitive Intelligence Brief. https://druglandscape.com/ci/crmd-001-deferiprone. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab